Reported about 10 hours ago
GeneDx Holdings' stock plummeted by 42.9% following the release of its Q1 2025 earnings report, which, despite exceeding revenue and adjusted earnings expectations, failed to meet market expectations built on past performance. The company's revenue grew 42% year-over-year to $87.1 million, but lowered expectations on future revenue growth and a decline in test volume contributed to investor disappointment.
Source: YAHOO